// App-Quantinova.ai

9515 : Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

Researchers

Presenter

  • Omid Hamid

Principal Investigators

  • Tae Min Kim

  • Sang-We Kim

  • Nehal J. Lakhani

  • Melissa Lynne Johnson

  • Roman Groisberg

  • Kyriakos P. Papadopoulos

  • John M. Kaczmar

  • Mark R. Middleton

  • Alexander I. Spira

  • Stephen K. Williamson

  • Guilherme Rabinowits

  • Rodolfo Gutierrez

  • Meredith McKean

  • Shuquan Chen

  • James Cassidy

  • Jayakumar Mani

  • Tasha Nicholle Sims

  • Glenn Kroog

Medical Centers

  • The Angeles Clinic and Research Institute Cedars-Sinai Medical Center, Los Angeles, CA.

  • Henry Ford Hosp, Detroit, MI

  • University of Ulsan College of Medicine, Seoul, South Korea,

  • START Midwest, Grand Rapids, MI

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Rutgers Cancer Institute of New Jersey, Piscataway, NJ

  • New Brunswick, NJ

  • START San Antonio, San Antonio, TX

  • MUSC Hollings Cancer Center, Charleston, SC

  • University of Oxford, Oxford, United Kingdom

  • US Oncology Research/Virginia Cancer Specialists, Fairfax, VA

  • University of Kansas Medical Center, Westwood, KS

  • Miami Cancer Institute, Baptist Health South Florida, Miami, FL

  • The Angeles Clinic and Research Institute Cedars-Sinai Medical Center, Los Angeles, CA.

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Locations

  • United States

  • United Kingdom

Companies

  • Regeneron Pharmaceut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03005782

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved